On October 4, Hong Kong pharmaceutical stocks plummeted. Fosun Pharma fell more than 15%, CanSino Bio fell by more than 17%, and WuXi Biologics fell by more than 6.6%.
It is reported that last Friday, the pharmaceutical giant Merck & Co. (known as “Merck” in the United States and Canada) announced that the oral anti-coronavirus experimental pill jointly developed by its partner Ridgeback Biotherapy can reduce hospitalizations or deaths by 50% risk.
After the data was released, the Dow component Merck (MRK.N) rose by more than 12% during the intraday session and closed at $81.45 per share, the highest intraday gain since 2009. The latest market value is 206.2 billion US dollars, or about 132.9 billion yuan.
However, vaccine stocks including Moderna fell collectively that day.
As of the close of the day, Modena was down 11.37%, Novavax was down 12.21%, BioNTech was down 6.67%, Pfizer was down 0.26%, Gilead Sciences was down 1.85%, and AstraZeneca was down 0.63%.
Daily Economic News Comprehensive Financial Association, Wind, and public information reports
Copyright Notice
1This article is the original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, extracting, copying or creating mirror images, etc., offenders must be investigated.
3Copyright cooperation telephone: 021-60900099.